Comparing the current results to its competitors, Fortrea Holdings Inc reported Revenue decrease in the 2 quarter 2026 year on year by -4.52 %, despite the revenue increase by the most of its competitors of 7.51 %, recorded in the same quarter.
May 31, 2024
Martin Silver Scholarship for Entrepreneurship: A Prestigious Opportunity for Aspiring InnovatorsThe Martin Silver Scholarship for Entrepreneurship has recently announced its 2024-2025 application cycle, offering a unique opportunity for ambitious undergraduate students seeking to pursue their entrepreneurial dreams. With a generous cash prize of $2,500, this esteemed scholarship aims to inspire and support the development of the next generation of business leaders. Founded by Martin Silver, a prominent figure in the finance and entrepreneurship sectors, this scholarship is a prestigious avenue for aspiring innovators to gain recognition and financial assistance for their ventures.Martin Silver, the visiona...
May 30, 2024
In an era where inclusivity and diversity are at the forefront of social, economic, and scientific progress, it is imperative that the medical field also reflects the diverse patient populations it serves. Fortrea, a pioneering company in clinical research, has unveiled a groundbreaking solution to enhance diversity and inclusion in this domain. Leveraging real-world data, patient insights, and an innovative systematic approach, Fortrea aims to design, operationalize, and measure the effectiveness of diversity action plans in clinical trials. Simultaneously, the company is expanding its non-commercial specialty pharmacy, FortreaRx, to cater to increased patient access needs. These initiatives mark a signific...
March 11, 2024
Fortrea Streamlines Strategic Focus with Divestiture of Endpoint Clinical and Patient Access BusinessesFortrea, a leading contract research organization, has announced the signing of a definitive agreement to divest its Endpoint Clinical and Fortrea Patient Access businesses to Arsenal Capital Partners. This move marks a significant step in Fortrea s strategic plan to streamline its operations and consolidate its focus as a pure-play contract research organization.The proposed divestiture comes as part of Fortrea s commitment to enhancing its core competencies and optimizing its service offerings. By offloading the Endpoint Clinical and Patient Access businesses, Fortrea aims to channel its resources towards...
February 20, 2024
Fortrea Expands Patient Access and Cold Chain Expertise with FortreaRx expansion, while Partnering with Veeva and Advarra for Streamlined Clinical Trial ExperienceIn a recent press release, Fortrea announced its expansion of the non-commercial specialty pharmacy, FortreaRx, to enhance patient access capabilities and further develop its cold chain expertise. The expansion aims to deliver flexible and scalable solutions to customers, ensuring life-changing medications are directly available to patients.With the growing demand for specialty medications, patient access and logistics management have become essential factors in healthcare. Fortrea recognized the need to enhance its capabilities in this area, leadi...
January 9, 2024
Coupled with the relentless innovation, the clinical trial experience is rapidly morphing. To facilitate this dynamic progression, Fortrea, a leader in healthcare innovation, announced an industry partnership with Veeva and Advarra. The innovative collaboration ventures to provide patients and sites with seamless access to study-related information through an integrated solution. A game-changing streamline in the usual work approach, the partnership aims to enhance efficiency while delivering a superior experience in clinical trials.Fortrea cherishes a reputation for being at the forefront of disruption, fostering faster and safer health solutions. This recent alliance reinforces its intent to anchor a more ...
Absci Corp's business model focuses on driving innovation in drug discovery and development through their integrated synthetic biology platform. They offer a comprehensive suite of services that enable clients to rapidly and efficiently discover, develop, and manufacture new biotherapeutics.
Amgen Inc.s business model focuses on leveraging advanced biotechnology to create therapeutic products for various diseases, particularly in the fields of oncology, inflammation, and cardiovascular health. The company invests heavily in research and development to drive innovation, while also utilizing strategic partnerships and acquisitions to enhance its product pipeline. Additionally, Amgen emphasizes a strong global commercial presence to maximize the accessibility and impact of its therapeutics in the healthcare market.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Sources:
Fortrea Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Fortrea Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
